Lunai Bioworks Statistics
Total Valuation
Lunai Bioworks has a market cap or net worth of $28.74 million. The enterprise value is $40.07 million.
Market Cap | 28.74M |
Enterprise Value | 40.07M |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
Earnings Date | Nov 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Lunai Bioworks has 23.18 million shares outstanding. The number of shares has increased by 69.27% in one year.
Current Share Class | 23.18M |
Shares Outstanding | 23.18M |
Shares Change (YoY) | +69.27% |
Shares Change (QoQ) | +7.43% |
Owned by Insiders (%) | 28.38% |
Owned by Institutions (%) | 6.25% |
Float | 13.01M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04
Current Ratio | 0.04 |
Quick Ratio | 0.02 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -25.56 |
Financial Efficiency
Return on equity (ROE) is -321.81% and return on invested capital (ROIC) is -18.57%.
Return on Equity (ROE) | -321.81% |
Return on Assets (ROA) | -13.53% |
Return on Invested Capital (ROIC) | -18.57% |
Return on Capital Employed (ROCE) | 88.63% |
Revenue Per Employee | n/a |
Profits Per Employee | -$6.14M |
Employee Count | 29 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.17% in the last 52 weeks. The beta is 0.39, so Lunai Bioworks's price volatility has been lower than the market average.
Beta (5Y) | 0.39 |
52-Week Price Change | -71.17% |
50-Day Moving Average | 2.03 |
200-Day Moving Average | 4.73 |
Relative Strength Index (RSI) | 32.39 |
Average Volume (20 Days) | 479,192 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -18.55M |
Pretax Income | -178.01M |
Net Income | -178.01M |
EBITDA | -18.42M |
EBIT | -18.55M |
Earnings Per Share (EPS) | -$10.78 |
Balance Sheet
The company has $480,551 in cash and $10.45 million in debt, giving a net cash position of -$9.96 million or -$0.43 per share.
Cash & Cash Equivalents | 480,551 |
Total Debt | 10.45M |
Net Cash | -9.96M |
Net Cash Per Share | -$0.43 |
Equity (Book Value) | -21.35M |
Book Value Per Share | -1.20 |
Working Capital | -28.11M |
Cash Flow
Operating Cash Flow | -7.87M |
Capital Expenditures | n/a |
Free Cash Flow | -7.87M |
FCF Per Share | -$0.34 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Lunai Bioworks does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -69.27% |
Shareholder Yield | -69.27% |
Earnings Yield | -591.30% |
FCF Yield | -26.16% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on September 30, 2025. It was a reverse split with a ratio of 1:10.
Last Split Date | Sep 30, 2025 |
Split Type | Reverse |
Split Ratio | 1:10 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |